Contraceptive Pills and Retinal Vascularization

Contraceptive Pills and Retinal Vascularization (Piluret)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03964636

Acronym

PILURET

Enrollment

Registered

2019-05-28

Start date

2019-07-17

Completion date

2022-12-01

Last updated

2023-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Combined Oral Contraceptives Intake

Keywords

OCT-A, combined oral contraceptives

Brief summary

The main hypothesis is the taking of combined 1st and 2nd generation or 3rd and 4th generation oral contraceptives is associated with a change in retinal micro-vascularization compared to the absence of combined oral contraceptive intake. Women of childbearing age will be recruited during their ophthalmologic consultation at the Rothschild Foundation, an OCT-A will be realized and data relating to their medical and ophthalmologic history and their oestro-progestative contraceptive intake will be collected. The objective is to find an association between retinal vascular density and combined oral contraceptives intake.

Interventions

DIAGNOSTIC_TESTOCT-A (optical coherence tomography)

Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Inclusion criteria

* for the control group : No Estro-progestin contraceptive treatment (oral, transdermal) for at least 6 months * for the cases under combined 1st and 2nd generation pills : Estro-progestin contraceptive treatment for at least 6 months * for the cases under combined 3rd and 2th generation pills: Estro-progestin contraceptive treatment for at least 6 months

Exclusion criteria

* Menopausal woman * Ametropia greater than + 3 hyperopia diopters or-3 myopia diopters * Astigmatism greater than 2 dioptres * Smoking patient (cigarette or e-cigarette) * Caffeine intake within 2 hours prior to the OCT-A exam * Any known retinal pathology * Antecedent of deep vein thrombosis or deep arterial thrombosis

Design outcomes

Primary

Measure	Time frame
Density of retinal vascular Plexus (quantitative variable expressed as a percentage) using OCT-A.	At the inclusion consultation

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026